Excelsior Biopharma Inc. - Laporan Laba Rugi (TTM)

Excelsior Biopharma Inc.
TW ˙ TPEX
NT$ 30.10 ↑0.55 (1.86%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Excelsior Biopharma Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1,524 1,444 1,443 1,382 1,315 1,338 1,167 997 872 672 686 719 730 772 774 799 830 862 882 871
Change (%) -5.25 -0.04 -4.21 -4.87 1.78 -12.83 -14.57 -12.55 -22.92 2.13 4.75 1.53 5.74 0.28 3.23 3.96 3.80 2.30 -1.24
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,182 1,134 1,143 1,098 1,040 1,045 875 704 570 385 405 441 451 465 451 444 453 480 496 501
Change (%) -4.12 0.87 -4.00 -5.25 0.48 -16.27 -19.59 -19.02 -32.51 5.41 8.78 2.35 2.94 -2.94 -1.63 2.04 6.00 3.35 0.98
% of Revenue 77.59 78.52 79.24 79.41 79.09 78.08 75.00 70.60 65.39 57.25 59.09 61.36 61.86 60.22 58.29 55.55 54.52 55.67 56.24 57.50
Gross Operating Profit 341 310 300 285 275 293 292 293 302 287 281 278 278 307 323 355 378 382 386 370
Change (%) -9.16 -3.37 -5.02 -3.40 6.70 -0.59 0.47 2.96 -4.81 -2.26 -1.08 0.23 10.29 5.14 10.02 6.37 1.17 0.98 -4.08
% of Revenue 22.41 21.48 20.76 20.59 20.91 21.92 25.00 29.40 34.61 42.75 40.91 38.64 38.14 39.78 41.71 44.45 45.48 44.33 43.76 42.50
SG&A 213 211 209 218 230 246 263 267 281 274 277 299 309 326 341 354 362 379 389 399
Change (%) -0.65 -0.91 3.92 5.59 7.12 6.75 1.76 4.95 -2.30 1.03 8.03 3.11 5.52 4.79 3.66 2.35 4.84 2.42 2.66
% of Revenue 13.96 14.64 14.51 15.74 17.47 18.39 22.52 26.83 32.20 40.81 40.37 41.64 42.28 42.19 44.09 44.28 43.59 44.02 44.08 45.82
R&D 62 57 61 53 53 56 52 60 54 42 43 42 55 63 71 75 75 84 88 92
Change (%) -7.06 6.17 -12.61 -0.57 5.92 -6.84 15.10 -9.62 -22.02 2.30 -3.44 32.56 12.83 13.67 5.16 0.97 10.82 4.74 5.07
% of Revenue 4.05 3.97 4.22 3.85 4.02 4.18 4.47 6.02 6.23 6.30 6.31 5.82 7.59 8.10 9.18 9.36 9.09 9.70 9.93 10.57
OpEx 1,457 1,402 1,414 1,369 1,323 1,347 1,190 1,031 905 701 726 782 815 853 863 872 890 943 972 992
Change (%) -3.74 0.82 -3.19 -3.35 1.85 -11.67 -13.35 -12.25 -22.51 3.51 7.77 4.26 4.59 1.23 1.02 2.07 5.93 3.10 2.02
% of Revenue 95.60 97.13 97.96 99.00 100.59 100.66 102.00 103.45 103.81 104.36 105.77 108.82 111.74 110.51 111.57 109.18 107.19 109.39 110.25 113.88
Operating Income 67 41 29 14 -8 -9 -23 -34 -33 -29 -40 -63 -86 -81 -90 -73 -60 -81 -90 -121
Change (%) -38.12 -29.09 -52.91 -155.60 13.86 165.52 47.85 -3.56 -11.75 35.10 60.08 35.17 -5.26 10.33 -18.08 -18.57 35.61 11.63 33.76
% of Revenue 4.40 2.87 2.04 1.00 -0.59 -0.66 -2.00 -3.45 -3.81 -4.36 -5.77 -8.82 -11.74 -10.51 -11.57 -9.18 -7.19 -9.39 -10.25 -13.88
Interest Expense -1 -2 -3 -4 -5 -5 -4 -4 -4 -4 -4 -4 -6 -6 -7 -8 -8 -8 -8 -8
Change (%) 66.43 39.96 28.45 20.15 -0.79 -1.10 -0.96 -1.10 -1.11 -0.92 -0.39 33.64 11.08 10.19 15.42 -5.19 4.48 3.18 -2.97
% of Revenue -0.08 -0.15 -0.21 -0.28 -0.35 -0.34 -0.38 -0.45 -0.50 -0.65 -0.63 -0.60 -0.79 -0.83 -0.91 -1.01 -0.92 -0.93 -0.94 -0.92
Net Income 55 35 25 12 -9 -16 -28 -38 -35 -34 -48 -71 -98 -91 -101 -86 -71 -99 -106 -133
Change (%) -36.36 -28.46 -54.06 -179.81 69.01 81.14 33.64 -6.59 -4.61 40.84 49.91 38.05 -7.50 10.73 -15.11 -17.38 39.64 7.28 25.48
% of Revenue 3.64 2.45 1.75 0.84 -0.70 -1.17 -2.43 -3.80 -4.06 -5.03 -6.93 -9.92 -13.48 -11.80 -13.03 -10.71 -8.51 -11.45 -12.01 -15.26

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista